312 related articles for article (PubMed ID: 32021227)
21. Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence.
Choi HM; Shin MS
Korean J Intern Med; 2020 May; 35(3):498-513. PubMed ID: 32392658
[TBL] [Abstract][Full Text] [Related]
22. Association Between Use of Sodium-Glucose Cotransporter-2 Inhibitors or Angiotensin Receptor-Neprilysin Inhibitor and the Risk of Atherosclerotic Cardiovascular Disease With Coexisting Diabetes and Heart Failure.
Lin YW; Lin CH; Lin CL; Lin CH; Lin MH
J Cardiovasc Pharmacol Ther; 2024; 29():10742484241233872. PubMed ID: 38438119
[TBL] [Abstract][Full Text] [Related]
23. Estimating the clinical and budgetary impact of using angiotensin receptor neprilysin inhibitor as first line therapy in patients with HFrEF.
Bergh N; Lindmark K; Lissdaniels J; Lanne G; Käck O; Cowie MR
ESC Heart Fail; 2024 Apr; 11(2):1153-1162. PubMed ID: 38279516
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Angiotensin Receptor-Neprilysin Inhibitor and Its Renal Outcome in Heart Failure Patients: A Systematic Review of Randomized Clinical Trials.
Almansouri NE; Bakkannavar S; Faheem Y; Jaiswal A; Shergill K; Boppana K; Nath TS
Cureus; 2024 Feb; 16(2):e54501. PubMed ID: 38516430
[TBL] [Abstract][Full Text] [Related]
25. Heart failure - what's new and what's changed?
Callan PD; Clark AL
Clin Med (Lond); 2016 Dec; 16(Suppl 6):s37-s42. PubMed ID: 27956439
[TBL] [Abstract][Full Text] [Related]
26. Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol.
Lee V; Zheng Q; Toh DF; Pua CJ; Bryant JA; Lee CH; Cook SA; Butler J; Díez J; Richards AM; Le TT; Chin CWL
Front Cardiovasc Med; 2023; 10():1248468. PubMed ID: 37674806
[TBL] [Abstract][Full Text] [Related]
27. Application of eligibility criteria from DAPA-HF, EMPEROR-Reduced, and PARADIGM-HF trials to a population with heart failure with reduced ejection fraction at a specialized cardiology Clinic in Medellin, Colombia: A retrospective cohort study.
Gonzalez-Franco J; Caicedo-Espinosa J; Cardona-Tobon C; Jaramillo-Jara N; Aguilar-Molina O; Jaimes-Barragan FA; Saldarriaga-Giraldo CI
Curr Probl Cardiol; 2024 Feb; 49(2):102193. PubMed ID: 37952788
[TBL] [Abstract][Full Text] [Related]
28. Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada.
Huitema AA; Daoust A; Anderson K; Poon S; Virani S; White M; Rojas-Fernandez C; Zieroth S; McKelvie RS
CJC Open; 2020 Sep; 2(5):321-327. PubMed ID: 32995716
[TBL] [Abstract][Full Text] [Related]
29. Highlights in heart failure.
Tomasoni D; Adamo M; Lombardi CM; Metra M
ESC Heart Fail; 2019 Dec; 6(6):1105-1127. PubMed ID: 31997538
[TBL] [Abstract][Full Text] [Related]
30. Exploring the Food and Drug Administration's review and approval of Entresto (sacubitril/valsartan).
Eadie AL; Brunt KR; Herder M
Pharmacol Res Perspect; 2021 May; 9(3):e00794. PubMed ID: 34087050
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin-Converting Enzyme and Heart Failure.
Álvarez-Zaballos S; Martínez-Sellés M
Front Biosci (Landmark Ed); 2023 Jul; 28(7):150. PubMed ID: 37525924
[TBL] [Abstract][Full Text] [Related]
32. Prolonged First-Dose Hypotension Induced by Sacubitril/Valsartan.
Hsiao FC; Chu PH
Acta Cardiol Sin; 2018 Jan; 34(1):96-98. PubMed ID: 29375230
[TBL] [Abstract][Full Text] [Related]
33. What Is the Clinical Utility of Cardiac Troponins in Heart Failure? Are They Modifiable Beyond Their Prognostic Value?
Agdashian D; Daniels LB
Curr Heart Fail Rep; 2023 Feb; 20(1):33-43. PubMed ID: 36719500
[TBL] [Abstract][Full Text] [Related]
34. Heart failure - what's new and what's changed?
Callan PD; Clark AL
Clin Med (Lond); 2017 Jul; 17(4):341-346. PubMed ID: 28765411
[TBL] [Abstract][Full Text] [Related]
35. Prescription Pattern in Angiotensin Receptor Neprilysin Inhibitor is Associated with Heart Failure Events.
Wu WT; Wang SH; Wang YL; Lin TH; Lai WT; Sheu SH
Acta Cardiol Sin; 2023 Jan; 39(1):144-150. PubMed ID: 36685156
[TBL] [Abstract][Full Text] [Related]
36. Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure.
Fala L
Am Health Drug Benefits; 2016 Mar; 9(Spec Feature):78-82. PubMed ID: 27668049
[No Abstract] [Full Text] [Related]
37. Current Drug Therapy in Chronic Heart Failure: the New Guidelines of the European Society of Cardiology (ESC).
Berliner D; Bauersachs J
Korean Circ J; 2017 Sep; 47(5):543-554. PubMed ID: 28955380
[TBL] [Abstract][Full Text] [Related]
38. An Up-to-Date Article Regarding Particularities of Drug Treatment in Patients with Chronic Heart Failure.
Buda V; Prelipcean A; Cozma D; Man DE; Negres S; Scurtu A; Suciu M; Andor M; Danciu C; Crisan S; Dehelean CA; Petrescu L; Rachieru C
J Clin Med; 2022 Apr; 11(7):. PubMed ID: 35407628
[TBL] [Abstract][Full Text] [Related]
39. Implications of Sex Differences on the Treatment Effectiveness in Heart Failure with Reduced Ejection Fraction Related to Clinical Endpoints and Quality of Life.
Aydin D; Allach Y; Brugts JJ
Curr Heart Fail Rep; 2024 Feb; 21(1):43-52. PubMed ID: 38060192
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
